PSNCBAM-1

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H21ClN4O
Molecular Weight	392.881
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(NC(=O)NC2=CC=CC(=C2)C3=NC(=CC=C3)N4CCCC4)C=C1

InChI

InChIKey=HDAYFSFWIPRJSO-UHFFFAOYSA-N

InChI=1S/C22H21ClN4O/c23-17-9-11-18(12-10-17)24-22(28)25-19-6-3-5-16(15-19)20-7-4-8-21(26-20)27-13-1-2-14-27/h3-12,15H,1-2,13-14H2,(H2,24,25,28)

HIDE SMILES / InChI

Molecular Formula	C22H21ClN4O
Molecular Weight	392.881
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17592509
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/21189269 | https://repository.library.northeastern.edu/files/neu:733/fulltext.pdf

PSNCBAM-1 is a novel negative allosteric modulator of the cannabinoid CB1 receptor. This molecule is shown to produce acute hypophagia and weight loss in male SD rats, and therefore may represent an alternative approach to the current strategies for the treatment of obesity. PSNCBAM-1 allosteric antagonism may provide viable therapeutic alternatives to orthosteric CB1 antagonists/inverse agonists in the treatment of CNS disease. No adverse or toxic effects were seen after long-term PSNCBAM-1 administration in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17592509	Negative Allosteric Modulator 42		45.2 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17592509	Primary		Preclinical	Unknown Approved Use Unknown
Central nervous system diseases 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21189269	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.	2007 Nov	17592509

Patents

Sample Use Guides

In Vivo Use Guide

30 mg/kg 30 min before the start of the dark phase at a dose volume of 5 ml/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

In HEK293-hCB1 cells, 10 uM PSNCBAM-1 was able to completely reverse either 10 nM CP55,940 or 1 uM AEA-induced inhibition of forskolin-stimulated cyclic AMP accumulation.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:02:39 GMT 2023` Edited by `admin` on `Sat Dec 16 09:02:39 GMT 2023`
Record UNII	P34SC5V6W2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PSNCBAM-1

Common Name

English

UREA, N-(4-CHLOROPHENYL)-N'-(3-(6-(1-PYRROLIDINYL)-2-PYRIDINYL)PHENYL)-

Systematic Name

English

N-(4-CHLOROPHENYL)-N'-(3-(6-(1-PYRROLIDINYL)-2-PYRIDINYL)PHENYL)UREA

Systematic Name

English

1-(4-CHLOROPHENYL)-3-(3-(6-(PYRROLIDIN-1-YL)PYRIDIN-2-YL)PHENYL)UREA

Systematic Name

English

Code System Code Type Description

WIKIPEDIA

PSNCBAM-1